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Abstract

RI
PT

Hypertriglyceridemia, defined as serum triglyceride (TG) levels > 150 mg/dL, now affects
over one-quarter of the U.S. adult population and is associated with an increased risk of
atherosclerotic

cardiovascular

disease.

Available

guidelines

for

managing

hypertriglyceridemia vary with respect to triglyceride thresholds and severity of disease.

SC

Lifestyle modifications and management of secondary causes (e.g., diabetes) remain the
first step in managing hypertriglyceridemia, with pharmacotherapy reserved to reduce

M
AN
U

the risk of pancreatitis and/or further reduce TG levels. Several classes of lipid-lowering
agents are available with variable TG-lowering efficacy. While there is no consensus
regarding the choice of initial TG-lowering pharmacotherapy, there is general agreement
that the decision depends on the degree of hypertriglyceridemia and atherosclerotic
cardiovascular disease risk. This review will discuss available and emerging lipid-

EP

499 mg/dL.

TE
D

lowering therapies for the management of moderately elevated TG, defined as TG 150-

AC
C

Key Words: hypertriglyceridemia, guidelines, fibrates, omega-3 fatty acids, dyslipidemia
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ACC= American College of Cardiology
ACCORD= Action to Control Cardiovascular Risk in Diabetes
AHA= American Heart Association
AIM-HIGH= Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High
Triglycerides: Impact on Global Health Outcomes
ANGPTL= angiopoietin-like protein
ApoC-III= apolipoprotein C-III
ASCVD= atherosclerotic cardiovascular disease
BAS= bile acid sequestrant
DGAT= diacylglycerol acyltransferase
ER= extended-release
FIELD= Fenofibrate Intervention and Event Lowering in Diabetes
FOURIER= Further Cardiovascular Outcomes Research with PCSK9 Inhibition in
Subjects with Elevated Risk
HDL-C= high-density lipoprotein cholesterol
HHS= Helsinki Heart Study
HPS2-THRIVE= Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of
Vascular Events
HR= hazard ratio
LDL-C= low-density lipoprotein cholesterol
LDL-R= low-density lipoprotein receptor
Lp(a)= lipoprotein(a)
LPL= Lipoprotein Lipase
MACE= major adverse cardiovascular event
MI= myocardial infarction
NCEP ATP III= National Cholesterol Education Program Adult Treatment Panel III
Non-HDL-C= non-high-density lipoprotein cholesterol
O3FA= omega-3 fatty acid
ODYSSEY= Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome
During Treatment with Alirocumab
PCSK9= Proprotein convertase subtilisin/kexin type 9
PPAR= perioxisome proliferator-activated receptor
TG = triglyceride
US = United States
VA-HIT= Veterans Affairs-High-Density Lipoprotein Cholesterol Intervention
VLDL-C= very low-density lipoprotein cholesterol
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Title:
Pharmacological Approaches For the Management of Patients with Moderately Elevated

RI
PT

Triglycerides (150-499 mg/dL)

Introduction

Targeting low-density lipoprotein cholesterol (LDL-C) with hydoxymethylglutaryl

SC

coenzymeA reductase (HMG-CoA) inhibitors, or statins, remains the primary therapy for
preventing atherosclerotic cardiovascular disease (ASCVD); however, it is well

M
AN
U

established that statin-treated patients have a high-degree of residual risk.1 Possible
explanations for this residual risk include inadequate reduction of LDL-C or the presence
of mixed dyslipidemia. The latter is characterized by low levels of high-density lipoprotein
cholesterol (HDL-C) and/or elevated triglycerides (TG); both of which are independently

TE
D

associated with increased ASCVD risk.2

Elevated TG levels have long been linked to an increased risk for ASCVD, but the direct
role TG play in the development and progression of atherosclerosis remains uncertain.2

EP

While average TG levels in the United States (US) have declined, the prevalence of
hypertriglyceridemia still exceeds 25% in the US.3,4 This persistent hypertriglyceridemia

AC
C

is likely due to the increasing prevalence of secondary factors independently associated
with hypertriglyceridemia, such as diabetes, obesity, metabolic syndrome, physical
inactivity, and western diet. As such, lifestyle modifications, including physical activity,
weight loss, and modification of dietary patterns should be provided to all patients with
elevated TG. Additionally, genetic factors contribute to hypertriglyceridemia in >95% of
individuals, which may necessitate the need for pharmacotherapy.4

4
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The purpose of this review is to discuss current perspectives from national guidelines
and the role of current and emerging lipid-lowering therapies for the management of

National Guideline Recommendations

RI
PT

moderately elevated TG (defined as TG values 150-499 mg/dL).

The American Heart Association (AHA) released a Scientific Statement on Triglycerides
and Cardiovascular Disease in 2011 to provide guidance on the importance of TG in

SC

assessing and managing ASCVD risk.2 While the definition for normal fasting TG
remained <150 mg/dL, as recommended by the Adult Treatment Panel III of the National

M
AN
U

Cholesterol Education Program5 (NCEP ATP III), the authors suggested that optimal
fasting TG levels should be <100 mg/dL. Significant emphasis was placed on initiation of
intensive lifestyle interventions, such as eliminating trans fatty acids, reducing simple
carbohydrates, implementing a Mediterranean-style diet, and weight loss of 5-10% body

TE
D

weight.2 Pharmacotherapy to lower TG was only recommended in individuals with TG
≥500 mg/dL, without preference toward any specific TG-lowering therapy.2

In 2012, the Endocrine Society Task Force developed Guidelines for the Evaluation and

EP

Treatment of Hypertriglyceridemia.6 While the Task Force again recognized TG <150
mg/dL as normal, authors modified the NCEP ATP III TG classification to further

AC
C

differentiate between moderate, severe, and very severe hypertriglyceridemia (Table 1).
The goal of this recommendation was to bring greater attention to very-high TG levels
and the risk for acute pancreatitis. Non-HDL cholesterol (non-HDL-C) was identified as
the treatment goal for patients with moderate hypertriglyceridemia, and maintaining TG
<1000 mg/dL was the goal for patients with very severe hypertriglyceridemia. Citing a
lack of conclusive evidence that TG-lowering therapies reduce ASCVD risk,
pharmacotherapy was recommended only in those with severe hypertriglyceridemia

5
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(>1000 mg/dL), with preference for fibrates over omega-3 fatty acids (O3FA) and niacin
due to subgroup analysis from clinical trials suggesting reduced ASCVD risk with fibrate
therapy in patients with TG >200 mg/dL. Lastly, statin monotherapy was not

NCEP
ATP III

High
Very-high
200-499
≥500
High
Very-high
AHA 2011
200-499
≥500
Moderate
Severe
Very severe
Endocrine Society Normal Mild HTG
HTG
HTG
HTG
2012
<150
150-199
200-999
1000-1999
≥2000
Normal Borderline
High
Very-high
NLA 2014
<150
150-199
200-499
≥500
Table 1: Classification of fasting triglyceride concentration by guideline.2,5–7
AHA= American Heart Association; HTG= hypertriglyceridemia; NCEP ATP III= National
Cholesterol Education Program Adult Treatment Panel III; NLA= National Lipid
Association.

SC

Borderline
150-199
Borderline
150-199

TE
D
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Normal
<150
Normal
<150

RI
PT

recommended for individuals with severe or very severe hypertriglyceridemia.6

The 2013 American College of Cardiology/American Heart Association (ACC/AHA)
Guideline on the Treatment of Blood Cholesterol was not intended to be a
guideline.1

As

such,

few

recommendations

regarding

EP

comprehensive

hypertriglyceridemia management were reported except that patients with TG ≥500

AC
C

mg/dL receive evaluation for secondary causes. In light of limited randomized controlled
trial evidence supporting the use of non-statin therapies in combination with statins, the
guideline referred readers to the 2011 AHA Scientific Statement on Triglycerides.

In 2014, the National Lipid Association (NLA) released recommendations based on a
broader review of available literature than the 2013 ACC/AHA Guideline, which only
evaluated evidence from randomized controlled trials. As a result, the NLA expert panel
embraced non-HDL-C as the primary target of therapy based on epidemiological studies

6
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and pooled analyses of intervention studies that suggest non-HDL-C is superior to LDLC as a predictor of ASCVD risk.7 One explanation for the improved predictive value of
non-HDL-C in patients with hypertriglyceridemia is that elevated TG levels impart greater

RI
PT

atherogenic burden due to increased very low-density lipoprotein cholesterol (VLDL-C)
levels and diminished plasma clearance of LDL-C via hepatic LDL receptors (LDL-R). In
2015, a second NLA report provided comprehensive lifestyle recommendations for
managing hypertriglyceridemia, including those recommended by the 2011 AHA

SC

statement.8 Nevertheless, the variability among these expert recommendations demand

M
AN
U

continuing discussion about appropriate management of hypertriglyceridemia.

Lipid-Lowering Pharmacotherapy and Effects on Triglycerides
Statins

Statins reduce LDL-C by inhibiting HMG-CoA, which results in hepatic LDL-R up-

TE
D

regulation to remove LDL-C from circulation.7 Because the LDL-lowering effect of statins
is dose related, the 2013 ACC/AHA guidelines recommend higher statin doses (or

EP

intensity) in patients at greater risk for ASCVD.1

The Individual Patient Meta-analysis of Statin Therapy in at Risk Groups: Effects of

AC
C

Rosuvastatin, Atorvastatin and Simvastatin (VOYAGER), examined dose-related
changes in lipid parameters with three statins.9 Low-intensity simvastatin 10 mg reduced
TG 9.3% from baseline, while high-intensity atorvastatin 80 mg lowered baseline TG
levels by 25.0%. A subgroup analysis of VOYAGER examined dose-related statin effects
in patients with baseline TG levels ≥177 mg/dL.10 Simvastatin 10 mg resulted in a 15.1%
TG reduction, while atorvastatin 80 mg resulted in a 31.3% reduction in TG levels. These

7
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results suggest that the TG-lowering effect of statins is dose related, with greater TGreductions seen in patients with higher baseline values.

RI
PT

The benefits of statin therapy for reducing major adverse cardiovascular events (MACE)
and ASCVD risk have been extensively described elsewhere, and are beyond the scope
of this article.1,7 Due to their ability to lower both ASCVD risk and TG levels, several

elevated TG and increased ASCVD risk.2,5–7

SC

guidelines recommend statin therapy as an initial agent for patients with moderately

Fibrates

TE
D
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Lipid-lowering medication
Triglyceride reduction (%)
Fibrates
20 - 50
Niacin
10 - 50
Omega-3 fatty acids
20 - 50
Statins
7 - 30
Ezetimibe
5 - 10
Bile acid sequestrants
0 (may increase up to 10%)
PCSK9 inhibitors
0 - 17
Table 2: Triglyceride lowering effect by medication class.

The fibric acid derivatives (fibrates including gemfibrozil and fenofibrate) are a class of

EP

lipid-lowering agents that significantly decrease TG (Table 2). Fibrates produce lipidlowering effects by activating the alpha subunit of perioxisome proliferator-activated

AC
C

receptors (PPARs).11 The PPAR-alpha belong to a superfamily of nuclear receptor
proteins that act as transcription factors, leading to lipid-modifying gene expression.
Activation of PPAR-alpha mediates TG reduction via three mechanisms: 1) suppressed
production of lipoprotein lipase (LPL) inhibitor apolipoprotein C-III (ApoC-III); 2) reduced
hepatic secretion of VLDL-C; and, 3) reduced hepatic TG production via beta-oxidation
(Figure 1).11

8
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A meta-analysis of 53 trials reported that fibrates reduce TG levels by 36% from baseline
versus placebo (p<0.00001).12 The average TG-lowering effect of gemfibrozil was 48%,
whereas fenofibrate reduced TG levels by 40%. Despite large reductions in TG, the

RI
PT

impact of fibrate therapy on ASCVD outcomes has been variable. In the pre-statin era,
trials such as the Helsinki Heart Study (HHS) and Veterans Affairs High-Density
Lipoprotein Cholesterol Intervention Trial (VA-HIT) demonstrated reduced MACE with

SC

gemfibrozil versus placebo in patients with TG ≥160 mg/dL.13,14 In the Fenofibrate
Intervention and Event Lowering in Diabetes (FIELD) trial, no difference in the composite
primary endpoint of MACE was observed in patients randomized to fenofibrate 200

M
AN
U

mg/day or placebo (5.9% versus 5.2%; p=0.16).15 However, a post-hoc analysis reported
a trend toward reduction in the primary endpoint in patients with metabolic syndrome,
including elevated TG levels (p=0.052).16 The lack of MACE reduction in the FIELD trial
may be related to increased statin use in the placebo group (17%) compared with the

TE
D

fenofibrate (8%) group during the study period.15 In the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial, adding fenofibrate to statin therapy significantly
reduced TG levels by 13.5% versus placebo (p<0.0001) in patients with TG >150 mg/dL

EP

at baseline, but did not reduce the composite primary endpoint of MACE.17 Again, prespecified subgroup analysis suggested a trend toward benefit in patients with TG ≥204

AC
C

mg/dL and HDL-C <34 mg/dL randomized to fenofibrate versus placebo (p=0.057).17
Furthermore, a recent post-trial follow-up to ACCORD showed that after an additional
five years, fenofibrate use was associated with a 27% relative risk reduction (HR, 0.73;
95% CI, 0.56-0.95) in the primary study outcome for the subgroup of patients with TG
≥204 mg/dL and HDL-C <34 mg/dL.18
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Figure 1: Targets of lipid-lowering medications (prefer color for on-line only)
ApoB= apolipoprotein B; ApoC-III= apolipoprotein CIII; BA= bile acids; BAS= bile acid
sequestrants; CE= cholesterol esters; CETP= cholesterylester transfer protein; DGAT=
diglyceride acetyltransferase; FFA= free fatty acids; IDL= intermediate-density
lipoprotein; HDL= high-density lipoprotein; LDL= low-density lipoprotein; LDL-R= lowdensity lipoprotein receptor; LPL= lipoprotein lipase; NPC1L1= Niemann-Pick C1-Like1;
O3FA= omega-3 fatty acids; PCSK9= proprotein convertase subtilisin/kexin type 9; TG=
triglycerides; VLDL= very-low-density lipoprotein.

EP

Niacin, also known as nicotinic acid or vitamin B3, is a water-soluble vitamin which at
high doses demonstrates the ability to lower total cholesterol, TG, VLDL-C, LDL-C,

AC
C

lipoprotein(a) [Lp(a)], while increasing HDL-C.19 Niacin decreases TG by inhibiting
diacylglycerol acyltransferase (DGAT) 2, an enzyme that catalyzes the formation of TG
from diacylglycerol and acyl-CoA.20 Niacin also inhibits lipolysis and subsequent release
of TG into the circulation.20

The Coronary Drug Project (CDP) was among the first clinical trials demonstrating
niacin’s ability to reduce TG. The CDP randomized male patients to one of six treatment

10
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arms, including niacin 3.0 g/day, with a primary aim to evaluate the efficacy of these
therapies on long-term ASCVD risk.21 After a 5-year follow-up period, niacin reduced TG
26.1% from baseline versus placebo. Additionally, a meta-analysis of 30 trials reported

RI
PT

an average TG reduction of 20% from baseline.22 Furthermore, the TG-lowering effect
was consistent for both intermediate-release and extended-release (ER) niacin, with

SC

reported 26% and 20% reduction, respectively.22

Reduction in ASCVD events has been reported with niacin monotherapy, although

M
AN
U

before the discovery of statins. In the CDP trial, niacin did not significantly reduce the
risk of death due to coronary artery disease, but did reduce risk of non-fatal myocardial
infarction (MI) by 27% (8.9% in niacin and 12.2% in placebo). At 15 years of follow-up,
nearly 9 years after trial end, mortality in the niacin group was 11% lower than placebo
(52.0% versus 58.2%, p=0.0004).23 Recently, two trials have evaluated the benefit of

TE
D

niacin/statin combination therapy to reduce residual risk in patients with a history of
ASCVD. In both the Atherothrombosis Intervention in Metabolic Syndrome with Low
HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and the Heart

EP

Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events
(HPS2-THRIVE) studies, adding ER niacin to statin therapy failed to reduce the primary

AC
C

endpoint of composite MACE in patients at LDL-C goal.24,25 However, higher rates of
select adverse effects (glucose intolerance, gastrointestinal symptoms) were reported in
the niacin treatment groups.

Omega-3 Fatty Acids (O3FA)
Omega-3 fatty acids (O3FA) are polyunsaturated fatty acids with the first double bond
occurring in the omega-3 position of the carbon backbone.26 Currently there are three
formulations of O3FA: eicosapentaenoic acid (EPA) ethyl ester, combination EPA and

11
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docosahexaenoic acid (DHA) ethyl esters, and EPA/DHA carboxylic acids;27 however,
insurance formularies will likely dictate which, if any, O3FA product is covered. There are
a variety of over-the-counter O3FA supplements, but due to lack of regulation, may

RI
PT

contain varying amounts and types of long-chain fatty acids.28 Although the exact
mechanism is unknown, O3FAs may exert their TG-lowering effects similar to fibrates,
including: increased hepatic beta-oxidation of fatty acids; increased LPL hydrolysis

SC

through activation of PPAR-alpha; and inhibition of ApoC-III.26

In placebo-controlled trials including patients with TG levels 200-500 mg/dL, O3FA

M
AN
U

reduced TG by 22% from baseline compared to placebo.27 In a meta-analysis of
placebo-controlled trials, O3FA demonstrated a 25-36% reduction in TG levels, with
greater reductions observed in patients with baseline values ≥177 mg/dL versus <177

TE
D

mg/dL (34% versus 25%).29

Multiple trials evaluating O3FA (at daily doses 1 to 2 g/day) to reduce cardiovascular risk
in patients with ASCVD have produced conflicting results.30 In a trial of recent MI

EP

patients, 95% of whom were not receiving lipid-lowering therapy post-MI, O3FA lead to a
10% reduction in the primary endpoint of death, non-fatal MI, and stroke versus placebo

AC
C

(p=0.048).27 However, several other studies in patients with ASCVD or at high risk were
unable to demonstrate significant MACE benefit of O3FAs versus placebo.27 A recent
AHA advisory statement suggests that O3FA supplementation is reasonable for
secondary prevention of cardiovascular events in patients with prevalent ASCVD, and to
reduce mortality and hospitalizations in patients with reduced ejection-fraction heart
failure.30

12
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Bile Acid Sequestrants (BAS)
The BAS are non-soluble resins that bind bile acids in the intestines, removing bile acids

RI
PT

from enterohepatic circulation, and ultimately leading to an up-regulation of LDL-R to
remove serum cholesterol.31 Use of BAS is associated with 15-30% LDL-C reduction,

SC

and up to a 10% increase in TG values.7

In one of the earliest primary-prevention trials, male patients with baseline LDL-C ≥190
mg/dL and TG of 154 mg/dL were randomized to BAS (cholestyramine) or placebo for

M
AN
U

an average of 7.4 years.32 Treatment with cholestyramine significantly lowered both total
cholesterol and LDL-C, and reduced the primary endpoint of MACE by 19% (p<0.05).
Patients who received BAS had a greater increase in TG at 1-year (10.2%) compared to
the placebo group (5.74%). By year seven, TG had increased by 17% to 182.9 mg/dL in

TE
D

the BAS group compared to an increase of 13.3% in the placebo group (significance not
reported).32 Given the risk of increased TG, the 2013 ACC/AHA guideline recommends

AC
C

Ezetimibe

EP

against use of BAS in patients with TG ≥ 300 mg/dL.1

Ezetimibe inhibits the Niemann-Pick C1-Like 1 transporter, thereby inhibiting absorption
of cholesterol at the intestinal border.33 As anticipated from this mechanism of action,
ezetimibe has little effect on TG. A meta-analysis of ezetimibe’s lipid-lowering effects
found ezetimibe 10 mg daily to be associated with a mean 8% reduction in TG versus
placebo (p<0.00001).34 Ezetimibe is indicated for use in combination with statin therapy
for primary hyperlipidemia (to reduce total-C, LDL-C, Apo B, and non-HDL-C) and in
combination with fenofibrate for patients with mixed dyslipidemia. Despite minimal TG-
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lowering effects, ezetimibe may be used in combination with other lipid-lowering agents
to further reduce LDL-C, without increasing TG.

RI
PT

Clinical ASCVD trials have primarily evaluated ezetimibe/statin combination versus statin
monotherapy or placebo. The Improved Reduction of Outcomes: Vytorin Efficacy
International

(IMPROVE-IT)

trial

found

that

combination

ezetimibe/simvastatin

SC

significantly reduced the composite MACE endpoint in patients with recent acute
coronary syndrome compared to simvastatin monotherapy (32.7% vs. 34.7%,

M
AN
U

respectively, p=0.016).35 Whether ezetimibe monotherapy reduces ASCVD risk in
patients with hypertriglyceridemia has not been evaluated by clinical trials.

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-I)
Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) prevents degradation

TE
D

of LDL-R, resulting in prolonged clearance of LDL-C from the plasma. Two humanized
monoclonal antibodies (evolocumab, alirocumab) that inhibit PCSK9 are approved for
LDL-C lowering in in patients with heterozygous familial hypercholesterolemia or clinical

EP

ASCVD, in addition to maximally tolerated statin therapy. Additionally, evolocumab is
approved for homozygous familial hypercholesterolemia patients who require additional

AC
C

LDL-C lowering despite lipid-lowering therapy.

A phase III study investigated the safety and efficacy of evolocumab in patients without
current lipid-lowering therapy or previous statin intolerance.36 Patients received
evolocumab subcutaneously, biweekly (140 mg) or monthly (420 mg), ezetimibe 10 mg
plus placebo injection, or placebo for 12 weeks. Biweekly and monthly evolocumab
treatment reduced TG 8.1% and 15.6% from baseline, respectively. Compared to
placebo, monthly evolocumab significantly reduced TG 17.7% from baseline (p<0.001).36

14
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More recently, a meta-analysis of 20 trials found that PCSK9-I treatment was associated
with a significant 12.2% TG reduction (p<0.00001).37

RI
PT

Recently, the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in
Subjects With Elevated Risk (FOURIER) trial found that evolocumab significantly
reduced the primary composite MACE endpoint compared to placebo (9.8% vs. 11.3%;
p<0.001) over a median follow up period of 2.2 years.38 Results of a second ASCVD

SC

outcome trial, Evaluation of Cardiovascular Outcomes After an Acute Coronary
Syndrome During Treatment With Alirocumab (ODYSSEY OUTCOMES), are expected

M
AN
U

in 2018.

TG-Lowering Therapies in Development

Volanesorsen (ISIS 304801) is an antisense oligonucleotide that targets ApoC-III mRNA
in the liver, which regulates TG production via inhibition of LPL. Two Phase II trials have

TE
D

been completed in subjects with elevated TG 350-2000 mg/dL and familial
chylomicronemia syndrome, an autosomal recessive disorder characterized by LPL
deficiency.39,40 In both studies, volanesorsen reduced TG by as much as 80%. Given

EP

that individuals with ApoC-III loss-of-function variants are at lower ASCVD risk, there is

AC
C

potential for such therapies to translate to improved clinical outcomes.
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Pemafibrate (K-877) is a highly-potent and selective antagonist of PPAR-alpha, which
promotes macrophage cholesterol efflux to HDL, and reduces inflammatory markers.41

RI
PT

In a phase II study, pemafibrate reduced TG by 43% and increased HDL-C 21%.42 As
such, an international, multi-centered cardiovascular outcomes trial, PROMINENT, is in
development with plans to randomize 10,000 high-risk patients with diabetes, with or
without ASCVD, to pemafibrate or placebo, in addition to background high-intensity

SC

statin therapy.43

M
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U

Angiopoietin-like proteins (ANGTL) 3 and 4 are highly expressed in the liver and potent
inhibitors of LPL, leading to decreased TG clearance. Importantly, individuals with an
ANGPTL loss-of-function mutation have lower TG levels and are at lower risk of CVD.
As such, there is great interest in developing inhibitors of ANGPTL proteins and early

TE
D

human clinical trials are ongoing.43–45

Discussion

Current guidelines addressing hypertriglyceridemia differ in their pharmacotherapy

EP

recommendations and choice of therapy seems to remain largely provider-dependent.
Additionally, definitions of hypertriglyceridemia and TG thresholds for initiating

AC
C

pharmacotherapy to reduce the risk of ASCVD and acute pancreatitis vary. The 2012
Endocrine Society’s recommendation to initiate TG-lowering pharmacotherapy for TG
>1000 mg/dL was a departure from previous guidelines, which recommended TGlowering medications for TG >500 mg/dL to prevent pancreatitis.2,5 A recent cohort study
reported that hypertriglyceridemia was associated with increased risks of acute
pancreatitis and MI, with the highest event rates occurring in patients with TG ≥443
mg/dL.46

Therefore,

in

accordance

with

previous

guidelines,

TG-lowering
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pharmacotherapy should be initiated in patients with TG ≥500 mg/L to reduce risk of
pancreatitis.

RI
PT

When treating TG <500 mg/dL, most guidelines recommend using non-HDL-C as the
primary treatment goal.5,7 In patients with moderately elevated TG (150-499 mg/dL),
multiple lipid-lowering agents (fibrates, niacin, O3FA, and high-intensity statins) have

SC

proven ability to reduce TG by ≥ 30%; however, evidence supporting ASCVD risk
reduction among non-statin therapies remains uncertain. Several guidelines recommend
statin therapy as an initial agent for TG 150-499 mg/dL because of proven ASCVD risk

M
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U

reduction and respectable TG-lowering efficacy.2,5–7 The TG-lowering effect of statins
appears dose-related, thus high-intensity statin should be initiated in most scenarios.
Subgroup analysis suggests that statins exhibits greater TG-lowering effects in patients
with higher baseline TGs (≥177 mg/dL) compared to patients with baseline TGs <177

TE
D

mg/dL.10

A practical approach to treating moderately elevated TG may be to initiate high-intensity
statin, followed by additional lipid-lowering agents as necessary to reach non-HDL-C

EP

goal. Additional agents to consider include fibrates, niacin, and O3FA because of larger
TG-lowering efficacy than other non-statin agents. Fibrates have substantial TG-lowering

AC
C

ability and may be a preferred agent to add to statin therapy due to once-daily
administration, favorable adverse effect profile, and generic product availability for most
formulations. Preference should be given to fenofibrate products over gemfibrozil due to
potential drug-drug interactions with several statins.47 While available clinical trials have
not demonstrated additional ASCVD risk reduction with fenofibrate/statin combination,
sub-group analysis suggests a benefit in patients with elevated TG.17,18
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In patients with TG 200-500 mg/dL, addition of O3FA to statin therapy further reduces
TG 20-30% from baseline.27 Because O3FA are available as a dietary supplement,
some patients may prefer this “natural” approach over prescription TG-lowering agents.

RI
PT

Potential limitations of O3FA include multiple capsules required to achieve TG-lowering
effects, and modest LDL-C increases with select O3FA products due to a shift toward
larger, more buoyant LDL particles.48 Furthermore, no randomized trials to date have

SC

investigated ASCVD risk reduction when adding prescription strength O3FA to statin
therapy, but two active clinical trials (REDUCE-IT and STRENGTH) are examining

M
AN
U

ASCVD outcomes in high-risk ASCVD patients with hypertriglyceridemia. These trials
are expected to be completed in 2017 and 2019, respectively, and will shed more light
on the impact of these agents in the context of modern treatment.27

The support for niacin in combination with statins has diminished, likely due to increased
risk of adverse effects and lack of ASCVD risk reduction reported by recent clinical

TE
D

trials.24,25 The American Diabetes Association (ADA) 2017 Standards of Care
recommend against routine combination of niacin with statins, but that fibrate therapy
may be considered in addition to statin therapy in men with TG ≥204 mg/dL and reduced

EP

HDL-C.49 The 2016 ACC Consensus Decision Pathway for non-statin therapies also
recommend against combination of niacin with statin therapy; however, this update

AC
C

primarily focused on non-statin agents to further lower LDL-C and did not specifically
address management of hypertriglyceridemia.50 Other lipid-lowering agents (BAS,
ezetimibe, PCSK9-inhibitors) demonstrate greater efficacy in lowering LDL-C than TG,
thus are preferred for patients receiving statin therapy who require further LDL-C
reduction.50 Newer agents are currently being investigated in Phase 2 and 3 trials.
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Conclusion
While much progress has been made in reducing TG values among US adults,
hypertriglyceridemia remains prevalent and contributes to increased risk of ASCVD and

RI
PT

acute pancreatitis. Lifestyle interventions should be recommended in all patients with
elevated TG levels, while selection of initial drug therapy depends on degree of
hypertriglyceridemia. For moderately elevated TG (150-499 mg/dL), high-dose statin

SC

therapy should be preferred because of significant TG-lowering ability and ASCVD risk
reduction benefits. If necessary, additional lipid-lowering agents may be added to reach

M
AN
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non-HDL-C goals in effort to lower ASCVD risk. For individuals with TG levels ≥500
mg/dL, non-statin therapies that significantly reduce TG are preferred initial agents to
achieve TG <500 mg/dL and reduce the risk of acute pancreatitis. Ongoing trials
evaluating the use of combination statin and TG-lowering therapies compared to statin
monotherapy will shed light on the ongoing dilemma surrounding the treatment of

TE
D

moderately elevated TG to reduce ASCVD risk.
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Elevated triglycerides (150-499 mg/dL) are associated with increased risk of ASCVD
Pharmacologic treatment for elevated triglycerides varies by guideline
High-intensity statin therapy can significantly lower triglycerides and ASCVD risk
Additional non-statin agents may be necessary to reach non-HDL-C goals
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